Get started
Author

Virginia Laspidea

Oncolytic DNX-2401 Virus for Pediatric Diffuse Intrinsic Pontine Glioma
2022 · Jaime Gállego Pérez-Larraya, Marc Garcia-Moure, et al. · New England Journal of Medicine · 279
PDF
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models
2019 · Naiara Martínez-Vélez, Marc Garcia-Moure, et al. · Nature Communications · 148
PDF
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory
2023 · Iker Ausejo-Mauleon, Sara Labiano, et al. · Cancer Cell · 108
PDF
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
2021 · Montserrat Puigdelloses, Marc Garcia-Moure, et al. · Journal for ImmunoTherapy of Cancer · 48
Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
2020 · Marc Garcia-Moure, Marisol Gonzalez-Huarriz, et al. · Clinical Cancer Research · 27
PDF
Exploiting 4-1BB immune checkpoint to enhance the efficacy of oncolytic virotherapy for diffuse intrinsic pontine gliomas
2022 · Virginia Laspidea, Montserrat Puigdelloses, et al. · JCI Insight · 24
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models
2024 · Daniel de la Nava, Iker Ausejo-Mauleon, et al. · Neuro-Oncology · 12
PDF
Local administration of IL-12 with an HC vector results in local and metastatic tumor control in pediatric osteosarcoma
2020 · Marta Zalacain, María Bunuales, et al. · Molecular Therapy — Oncolytics · 10
PDF
Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models
2024 · Iker Ausejo-Mauleon, Naiara Martinez-Velez, et al. · JCI Insight · 9
PDF
Galectin-3 inhibition boosts the therapeutic efficacy of Semliki Forest virus in pediatric osteosarcoma
2022 · Guillermo Herrador-Cañete, Marta Zalacain, et al. · Molecular Therapy — Oncolytics · 8
PDF
Targeting the CD40 costimulatory receptor to improve virotherapy efficacy in diffuse midline gliomas
2025 · Sara Labiano, Javier Marco-Sanz, et al. · Cell Reports Medicine · 6
The emerging field of viroimmunotherapy for pediatric brain tumors
2024 · Marc Garcia-Moure, Virginia Laspidea, et al. · Neuro-Oncology · 6
PDF
P17.15.a Thank Phase I Trial of Dnx-2440 Oncolytic Adenovirus in Patients With First or Second Recurrence of Glioblastoma: Preliminary Results
2023 · J Gallego Perez-Larraya, D de la Nava, et al. · Neuro-Oncology · 4
PDF
P17.14.b Phase I Trial of Dnx-2401 Oncolytic Adenovirus Combined With a Short Course of Dose-dense Temozolomide for Recurrent Glioblastoma
2023 · J Gallego Perez-Larraya, M García-Moure, et al. · Neuro-Oncology · 4
PDF
745 Oncolytic adenovirus expressing 4-1BBL demonstrates a significant increase of survival in Diffuse Midline Glioma models
2021 · Virginia Laspidea, Sara Labiano, et al. · Regular and Young Investigator Award Abstracts · 2
PDF
High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al. · Cancer Research · 1
Immu-56. Targeting Nono in Glioma Viroimmunotherapy
2023 · Andrew Gillard, Dong Ho Shin, et al. · Neuro-Oncology · 1
PDF
DIPG-22. Modifying the tumor microenvironment with a TIM-3 monoclonal antibody as a therapeutic strategy for DIPGs
2022 · Iker Ausejo-Mauleon, Sara Labiano, et al. · Neuro-Oncology · 1
283 TIM-3 blockade modulates the tumor microenvironment improving the outcome of preclinical pediatric diffuse midline glioma models
2021 · Iker Ausejo-Mauleon, Sara Labiano, et al. · Regular and Young Investigator Award Abstracts · 1
PDF
Abstract 3053: Armed oncolytic virus for treatment of pediatric diffuse intrinsic pontine glioma
2021 · Sumit Gupta, Virginia Laspidea, et al. · Cancer Research · 1
Supplementary Figure 9 from High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al.
Supplementary Table 5 from High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al.
Figure 1 from High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al.
Supplementary Figure 10 from High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al.
Supplementary Table 7 from High-Risk Rhabdomyosarcomas Feature a Convergent Cell State
2026 · Holly J. Whitfield, Nathaniel D. Anderson, et al.
Works count: 101
Citation count: 700
H-index: 9
I10-index: 8
Year
Topic
Type